Cas:887594-18-5 (4-phenoxyphenyl)methylhydrazine manufacturer & supplier

Chemical Name:(4-phenoxyphenyl)methylhydrazine

CAS.NO:887594-18-5

Synonyms:(4-phenoxyphenyl)methylhydrazine

Molecular Formula:C₁₃H₁₄N₂O

Molecular Weight:214.26300

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:47.28000

Exact Mass:214.11100

LogP:3.53340

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like (4-phenoxyphenyl)methylhydrazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(4-phenoxyphenyl)methylhydrazine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,(4-phenoxyphenyl)methylhydrazine Use and application,(4-phenoxyphenyl)methylhydrazine technical grade,usp/ep/jp grade.

Related News: After examining all the evidence, it was clear that more plausible explanations for the AML cases included the conditioning treatment the patients received to clear out bone marrow cells and the higher risk of blood cancer in people with sickle cell disease. Dipicrylamine, ammonium salt manufacturers The FDA has already clashed with COVID vaccine heavyweights Pfizer and BioNTech over the immediate need for boosters for the broader population. While the drugmakers argue a third shot would offer the highest level of protection, both the CDC and FDA immediately came out against that assertion. 3(2H)-Pyridazinone, 6-phenyl-5-[(phenylthio)methyl]- suppliers It is always advisable for companies to start the clinical study responsibilities early on to combat unforeseen challenges that require more time. N,3-dimethylbut-3-en-2-amine vendor & factory After examining all the evidence, it was clear that more plausible explanations for the AML cases included the conditioning treatment the patients received to clear out bone marrow cells and the higher risk of blood cancer in people with sickle cell disease.,The FDA has already clashed with COVID vaccine heavyweights Pfizer and BioNTech over the immediate need for boosters for the broader population. While the drugmakers argue a third shot would offer the highest level of protection, both the CDC and FDA immediately came out against that assertion.